VIP
Also known as Vasoactive intestinal peptide
Studied for: airway, gut & immune signaling
Vasoactive intestinal peptide is a 28-amino-acid neuropeptide of the secretin family, first isolated from porcine intestine. Research examines its role as an inhibitory neurotransmitter in the airways, a regulator of gut motility and secretion, and a modulator of immune cell signaling.
Last reviewed September 26, 2026
How it is thought to work
Research investigates VIP for signaling through the VPAC1 and VPAC2 G-protein-coupled receptors, studied for smooth-muscle relaxation, vasodilation and the modulation of inflammatory cytokine release.
- VPAC ReceptorsStudied for activation of VPAC1 and VPAC2 receptors expressed on smooth muscle, epithelium and immune cells.
- Airway ToneExplored as an inhibitory neurotransmitter in the airways in models of bronchial smooth-muscle relaxation.
- Immune ModulationStudied for influence on cytokine signaling and immune cell behavior in models of inflammation.
- Route studied
- Subcutaneous
- Research status
- Early clinical
VIP has been studied in small human studies and a multicenter randomized controlled trial of intravenous aviptadil in critical COVID-19 respiratory failure, alongside inhaled use in pulmonary hypertension, but no phase 3 program is documented here.
Research
What the research covers
What research examines
- Pulmonary hypertension via inhaled administration
- Critical COVID-19 respiratory failure (intravenous aviptadil)
- Pulmonary disease biology
- Osteoarthritis mechanisms
- VIP interneurons in neurodevelopmental disorders
Reported effects in studies
- Human safety data for subcutaneous research protocols are limited
- Adverse events are not summarized in the cited study titles
- Excess VIP secretion from VIP-secreting tumors is a recognized clinical condition described in review literature
Studied range
What research protocols have used
Research protocols have used 50–100 mcg per administration, twice daily, in 8-week blocks with 4 weeks off.
For research use only. These figures summarize published research protocols. They are not instructions or medical advice.
Every CoreX order ships with a per-lot protocol guide.
Open the reconstitution calculatorStudies
Cited research
- The Use of IV Vasoactive Intestinal Peptide (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.
Critical care medicine · 2022 · RCT · PMID 36044317
- Inhalation of vasoactive intestinal peptide in pulmonary hypertension.
The European respiratory journal · 2008 · PMID 18978135
- The role of vasoactive intestinal peptide in pulmonary diseases.
Life sciences · 2023 · Review · PMID 37742737
- Aviptadil (Senatek).
Current opinion in investigational drugs (London, England : 2000) · 2001 · Review · PMID 11566015
- Vasoactive intestinal peptide.
Journal of endocrinological investigation · 1986 · Review · PMID 2872248
FAQ
Questions about VIP
VIP, or vasoactive intestinal peptide, is an endogenous neuropeptide that has been reviewed in the endocrinology literature since at least the 1980s. It is found in the gut, lungs, and nervous system, including specialized VIP interneurons in the brain. A synthetic form, known as aviptadil, has been used in clinical research. CoreX supplies VIP for laboratory research use only.
VIP acts as a signaling peptide across several tissues. Its name reflects its early characterization as a vasoactive substance originating in the intestine. Review articles describe roles in pulmonary tissue and joint biology, and neuroscience research has examined VIP-expressing interneurons in brain circuit development. The precise mechanisms relevant to each research area remain under investigation, and much of the mechanistic literature consists of reviews rather than definitive trials.
Research has studied inhaled VIP in pulmonary hypertension and intravenous aviptadil in patients with critical COVID-19 respiratory failure in a 60-day multicenter randomized controlled trial. Reviews have examined VIP in pulmonary diseases, osteoarthritis, and neurodevelopmental disorders involving VIP interneurons. These findings describe research interest and early evidence rather than established outcomes, and results in one setting should not be assumed to apply to others.
Human safety data for subcutaneous VIP research protocols are limited, and adverse events are not summarized in the cited study titles. Review literature describes VIP-secreting tumors, a condition in which excessive endogenous VIP production causes clinical illness, which illustrates that sustained high VIP levels have physiological effects. Researchers should consult the full clinical publications for detailed safety reporting from the inhaled and intravenous studies.
Research protocols have used 50–100 mcg per administration, twice daily, by the subcutaneous route, in 8-week blocks followed by 4 weeks off. This describes what protocols have used and is not a recommendation. Published clinical studies have also used other routes, including inhalation and intravenous infusion. Each CoreX order ships with a protocol guide for laboratory research reference.
Ask about VIP
Plain answers from our library: the science, the studied ranges and our products. It can be wrong, and it does not give medical advice.
AI answers can be wrong. Research use only.